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Abstract
Background
Angiotensin-converting enzyme (ACE), which metabolizes many peptides and plays a key
role in blood pressure regulation and vascular remodeling, as well as in reproductive func-
tions, is expressed as a type-1 membrane glycoprotein on the surface of endothelial and
epithelial cells. ACE also presents as a soluble form in biological fluids, among which semi-
nal fluid being the richest in ACE content - 50-fold more than that in blood.
Methods/Principal Findings
We performed conformational fingerprinting of lung and seminal fluid ACEs using a set of
monoclonal antibodies (mAbs) to 17 epitopes of human ACE and determined the effects of
potential ACE-binding partners on mAbs binding to these two different ACEs. Patterns of
mAbs binding to ACEs from lung and from seminal fluid dramatically differed, which reflects
difference in the local conformations of these ACEs, likely due to different patterns of ACE
glycosylation in the lung endothelial cells and epithelial cells of epididymis/prostate (source
of seminal fluid ACE), confirmed by mass-spectrometry of ACEs tryptic digests.
Conclusions
Dramatic differences in the local conformations of seminal fluid and lung ACEs, as well as
the effects of ACE-binding partners on mAbs binding to these ACEs, suggest different regu-
lation of ACE functions and shedding from epithelial cells in epididymis and prostate and
endothelial cells of lung capillaries. The differences in local conformation of ACE could be
the base for the generation of mAbs distingushing tissue-specific ACEs.
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Introduction
Angiotensin I-converting enzyme (ACE, CD143) is a Zn2+ peptidyldipeptidase which plays key
roles in the regulation of blood pressure and in the development of vascular pathology and
remodeling. ACE is constitutively expressed on the surface of endothelial cells, epithelial and neu-
roepithelial cells and cells of the immune system (macrophages, dendritic cells, reviewed in [1–3].
In addition to membrane-bound ACE, blood, seminal fluid and other biological fluids con-
tain a variable amount of soluble ACE. Blood ACE likely originates from the vascular endothe-
lium [4], mostly lung endothelial cells, because lung capillaries exhibit nearly 100% ACE
expression compared to only 10–15% ACE-positive capillaries in the systemic circulation [5].
ACE enters the circulating pool via a proteolytic cleavage from the cell surface [6–7] by still
unidentified membrane-bound ACE secretase [8].
Human seminal fluid ACE likely originates from glandular epithelial cells of epididymis and
prostate, that express significant amount of somatic ACE [9–14]. Human seminal fluid con-
tains 50-fold more ACE than blood [15–17]. However, the level of somatic ACE expression in
male reproductive tract is comparable to somatic ACE expression in endothelial cells of
capillaries [14, 18]. Therefore extremely high level of ACE in seminal fluid could be due to the
higher ratio of the surface of epithelial cells producing ACE in the reproductive tract to the vol-
ume of seminal fluid than the ratio of the surface of ACE-producing endothelial cells of lung
capillaries to the blood volume. Alternatively, it could be due to increased shedding of ACE
from the surface of epithelial cells of epididymis and prostate in comparison to ACE shedding
from endothelial cells.
There are at least two possible reasons of increased shedding: 1) Increased expression of
ACE secretase in glandular epithelial cells of epididymis and prostate (but unfortunately the
nature of ACE secretase is still unknown); 2) Different conformations of ACE on the surface of
endothelial and epithelial cells, which, in turn, may lead to either different exposure of stalk
region, where ACE secretase cleaves ACE from cell surface, or different regulation of ACE
shedding from different cells by the presence of putative ACE-binding proteins/ACE effectors.
Species specificity of ACE is apparent; however, more subtle tissue specificity of the enzyme
can influence ACE functions both in vitro and in vivo. We demonstrated recently that the pat-
tern of mAbs binding to the conformational epitopes on the surface of ACE, “conformational
fingerprint of ACE”, is an extremely sensitive marker of the local conformational changes in
ACE molecule due to mutations, denaturation, inhibitor binding, presence of membrane
anchor, etc. We proved the concept that the conformation of ACE is cell-and tissue-specific
and stems likely from different post-translational modifications, including different glycosyla-
tion, on the example of ACE from endothelial cells and ACE from macrophages and dendritic
cell of sarcoid granuloma. The ACE fingerprint, therefore, has a potential for the disclosure of
the cells from which ACE originates [19].
We applied this approach here to detect structural (conformational) differences of ACEs
originated from endothelial cells (lung ACE) and epithelial cells (male reproductive tract). We
believe that structural differences in ACEs from different organs, which we found, could be a
base for the development of antibodies, which will distinguish ACEs shed to the blood circula-
tion from different organs by their origin.
Experimental Section
ACEs from different sources
The work was carried out in accordance with The Code of Ethics of World Medical Association
(Declaration of Helsinki) and was approved by the Institutional Review Boards of the Bakulev
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LMW, low molecular weight.
Center of Cardiovascular Surgery, Moscow University and the University of Illinois at Chicago.
Written informed consent from the donor or the next of kin was obtained for the use of this
sample in research. Human citrated plasma, seminal fluid, lung, prostate and epididymis tissue
homogenates were used as sources of somatic two-domain ACE. Lung and seminal fluid ACEs
were purified using lisinopril affinity chromatography exactly as in [20]. Estimation of the per-
centage of ACE molecules carrying hydrophobic anchor (membrane form) in lung ACE prepa-
ration was performed by phase separation in Triton X-114 solution [21].
ACE activity assay
ACE activity in blood plasma, seminal fluid, homogenates of human organs was measured
using a fluorimetric assay with two ACE substrates, 2 mM Z-Phe-His-Leu (ZPHL) and 5 mM
Hip-His-Leu (HHL), at pH 8.3 [22]. Briefly, 20 ul aliquots of samples were added to 200 ul of
ACE substrate and incubated for the appropriate time at 37°C. The His-Leu product was
quantified fluorimetrically via complexing with o-phtaldialdehyde. Inhibition of ACE
activity by ACE inhibitors was performed by incubation of ACE (2 nM) with up to 0.1 uM
enalaprilat and up to 1 uM teprotide, at pH 7.5 for one hour and then measurement of resid-
ual ACE activity with 0.2 mM ZPHL as a substrate at the same pH value. Inhibition of ACE
activity with anti-catalytic anti-ACE mAbs was performed by 10 ug/ul mAbs as described in
[23].
Immunological characterization of ACEs
Ninety six-well plates (Corning, Corning, NY) were coated with anti-ACE mAbs via goat anti-
mouse IgG (Pierce, Rockford, IL) bridge [24] and incubated with different sources of ACE,
which were equilibrated for ACE activity with ZPHL as a substrate. After washing off unbound
ACE, plate-bound ACE activity was measured by adding a substrate for ACE (ZPHL) directly
into the wells [24]. Sixteen mAbs to human ACE were generated in our lab [19], while mAb
BB9 [25] was kindly provided by Paul J Simmons (then Brown Foundation of Molecular Medi-
cine, University of Texas Health Science Center, Houston, TX, USA).
Immunochemical characterization of ACE in the presence of different effectors was per-
formed as described above, ACE solution being mixed with a solution of effectors just before
application on the plate wells. The effectors used were heat-inactivated citrated plasma, heat-
inactivated seminal fluid, 3 kDa filtrate of human citrated plasma, albumin, and bilirubin.
Heat-inactivated plasma and seminal fluid were prepared by heating at 65°C for 45 min and
checked for the absence of ACE activity; 3 kDa filtrate was prepared by filtration of human
citrated plasma on Vivaspin 500 MWCO 3000 concentrator (GE Health Care, Sartorius Corp.,
Bohemia, NY) at 4°C and 12,000 g for 2 h.
Immune responce to ACE from seminal fluid
Mice were immunized five times with pure seminal fluid ACE at 10ug per i.p. injection. The
sera were tested against this immunogen in ELISA and against two ACEs, pure seminal fluid
ACE and pure lung ACE, in plate precipitation assay. Upon reaching antibody titers 5x105-106,
as measured by ELISA, mice were boosted and isolated splenocytes were fused to mouse mye-
loma cells 653-Ag8. The resulting populations grown in 96-well plates were subjected to pri-
mary screening with two pure ACEs, seminal fluid ACE and lung ACE, in plate precipitation
assay in simultaneous experiments.
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Estimation of the size of the surface influenced by oligosaccharide
Sialylated biantennary complex oligosaccharide was modeled with the program Insight II
(Accelrys Inc., San Diego, CA) and attached to the each potential site of glycosylation on the
surface of the C domain (PDB 108A) of ACE. Molecular dynamics during 500 psec was applied
for the estimation of the movement of the glycan and the neighboring amino acid residues
within 15 Å from definite Asn residue.
Desialylation of ACE
Desialylation of ACE was performed by neuraminidase from Vibrio Cholerae (Sigma-Aldrich,
MO) in 0.1 MMES buffer, pH 6.0, containing 0.15 M KCl and 0.4 mM CaCl2, at 25°C. The pro-
cess was controlled by ion-exchanged chromatography of 1 uM solutions of native and desialy-
lated ACEs on Agilent1100 chromatograph with electrochemical cell. Chromatograms of
native and desialylated ACEs were treated by the program Agilent Chemstation A.09.01 (Santa
Clara, CA). For the calibration curve, solutions of neuraminic acids of 1, 10, and 20 uM were
used.
Protein digestions and mass spectrometry
The lung ACE and seminal fluid ACE were subjected to electrophoresis in denaturing condi-
tions. For each ACE sample, two protein bands on an electrophoretic gel were obtained, which
were further subjected to mass spectrometry peptide fingerprinting as follows. A piece of ACE
band from electrophoretic gel was transferred into a test tube, washed from the dye, and then
the protein was digested by trypsin as is described elsewhere [26]. Peptides were extracted with
30% acetonitrile containing 0.1% trifluoroacetic acid and subjected to MALDI-TOF mass spec-
trometry. All mass spectra were obtained on a time-of-flight MALDI-TOF UltrafleXtreme
mass spectrometer (Bruker Daltonics, Germany) using 2,5-dihydroxybenzoic acid as a matrix.
The data were analyzed by MASCOT program (www.matrixscience.com) with the use of
SWISS-PROT database, and then using the ExPASy online tools, FindPept (www.expasy.org/
findpept) and GlycoMod (web.expasy.org/glycomod). The FindPept tool was used to find addi-
tional matching to mass spectrometry data, peptides, such as C-terminal (unspecific) tryptic
peptides which could not be discriminated by the MASCOT program. Non-matched peaks
from the mass spectra were further analyzed with the GlycoMod tool in order to find possible
glycopeptides and N-linked glycans in the ACE. The possibility of cysteine modification with
acrylamide and methionine oxidation, which are typical variable modifications in mass spec-
trometry of proteins, was included in the analysis as well as the possibility for one or two
missed cleavages with trypsin. Since a search with the GlycoMod tool is based on a comparison
of experimental masses of glycopeptides with theoretical ones, its results sometimes contain
false positive hits (displaying rather exotic glycan structures). So, finally only those N-linked
glycan structures were taken into consideration and further manual analysis that matched the
oligosaccharide compositions contained in the UniCarbKB database.
Results and Discussion
Immunological characterization of ACEs purified from human lung and
seminal fluid
We characterized the conformation of pure lung and seminal fluid ACE, using a panel of mAbs
directed against 17 different epitopes located on the N and C domains of catalytically active
human ACE - “conformational fingerprint of ACE”[19]. As apparent in Fig 1A, the immuno-
precipitation profile of pure ACEs from seminal fluid and lung dramatically differed. Because
Tissue Specificity of ACE
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Fig 1. Immunological characterization of different ACEs.Conformational fingerprinting of different ACEs with a set of mAbs to ACE. Seventeen
monoclonal antibodies (mAbs) were used to precipitate ACE from different sources. Immunoprecipitated ACE activity is presented as a normalized value
(“binding ratio” expressed as a percentage of the activity of ACE from one source to that from another source) to highlight differences in immunoprecipitation
pattern (“conformational fingerprint”) among different ACE variants. (A). The ratio of precipitated activity of pure seminal fluid ACE to that of pure lung ACE.
B-C. The ratio of precipitated activity of ACE from prostate homogenate (B) or epididymis homogenate (C) to that of lung homogenate. Data are presented as
Tissue Specificity of ACE
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we mapped the epitopes for all these mAbs to human ACE [27–31] we can make a conclusion
that seminal fluid ACE (originated from epithelial cells of epididymis and prostate) and lung
ACE (originated from endothelial cells) exhibit different conformations of their surface. Most
probable, these differences are caused by different glycosylation of ACE from different cells.
Tissue- and cell-specific post-translational modifications (PTM) are common for various
proteins [32–36]. PTMs precisely regulate the functions of proteins by inducing conforma-
tional changes which subtly or dramatically alter the protein surface or its overall tertiary struc-
ture. The most common PTM is glycosylation, however, phosphorylation, methylation,
acetylation, deamidation, etc. are also widespread [32, 35–37].
Somatic ACE represents a characteristic N-glycosylated glycoprotein, exact glycan struc-
tures of which, as well as exact locations of actually present oligosaccharide chains on the sur-
face of the protein globule, can vary with different protein sources. The sequence of human
somatic ACE contains 17 potential sites for N-glycosylation [38]. The structure and exact posi-
tions of glycan moiety in human somatic ACE from different tissues are still poorly investi-
gated. It was reported that seven of the 17 potential sites are glycosylated in human seminal
plasma ACE (Asn9, in particular), the majority of glycans belonging to biantennary structures
[39]. Human kidney ACE was reported to have at least six N-glycosylated sites, residues 9, 25,
82, 117, 480, and 913 [26]. Human plasma proteomics revealed three glycosylation sites in
blood ACE, Asn480, 666, and 685 [40].
It was shown previously that somatic ACE contains mostly complex-type oligosaccharides
[26, 39]. Modeling of the structure of the common sialylated biantennary complex oligosaccha-
ride and subsequent molecular dynamics of single-domain ACE with attached oligosaccharide
allowed us to show that the contact of the oligosaccharide chain with the surface of the enzyme
can occur within the area about 200–300 Å. As epitopes for mAbs are usually 400–750 Å [27],
it is obvious that the presence or absence of the oligosaccharide (as well as its definite structure,
i.e. the number of antennae, sialylation, fucosylation, etc.) within an epitope can hugely influ-
ence on mAbs binding.
Seminal fluid ACE and lung ACE possess rather equal masses as was shown by SDS-PAGE
(not shown) which indicates on the absence of major differences in the degree of glycosylation
of these ACEs. However, some evidence of different modes of glycosylation of lung ACE and
seminal fluid ACE was obtained by the analysis of the action of neuraminidase on both
enzymes. It was found that while desialylation of seminal fluid ACE did not result in the
appearance of any neuraminic acid on the ion-exchange chromatogram, desialylation of lung
ACE resulted in the appearance of 5 neuraminic acid residues per molecule of the enzyme (not
shown). It is known that human lung ACE is characterized by a lower pI value (5.1) compared
to that of kidney ACE (5.2) which was attributed to a bigger number of neuraminic acid resi-
dues in lung ACE glycans [41]. On the other hand, the number of neuraminic acid residues per
molecule of kidney ACE was reported to be equal to 5.9 [42]. So, based on a lower pI value of
lung enzyme, we might expect much larger content of neuraminic acid residues per molecule
of lung ACE than 5 observed in our work. Moreover, we did not found any neuraminic acid
residues for ACE from kidney as well (not shown). It seems, that desialylation in experimental
conditions was not complete which resulted in underestimated values, if any, of neuraminic
acid residues per ACE molecule. Thus, the difference in neuraminic acid residues content
between seminal fluid ACE and lung ACE can not be considered as quantitative finding but
rather an indication that the degree of sialylation of seminal fluid ACE is much less than that of
a mean of at least 3 independent experiments. Ratios increased more than by 20% are highlighted in orange and more than by 100% are highlighted in red.
Ratios decreased more than by 20% are highlighted in yellow, more than by 50% in deep blue.
doi:10.1371/journal.pone.0143455.g001
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lung ACE. The molecular basis for this phenomenon could be that, while the composition of
the oligosaccharide chains in lung ACE is still unknown, seminal fluid ACE contains five com-
plex-type glycans, which can contain sialic acid residues, while two other glycans in this ACE
represent oligomannose-type glycans [39]. In addition, it is interesting that from 5 sialic acid
residues found for lung ACE, three residues corresponded to N-acetyl-neuraminic acid
whereas two residues represented N-glycolyl-neuraminic acid, which was reported earlier to be
abundant in testicular ACE but not found in kidney ACE [39].
An analysis of the conformational fingerprint of lung ACE and seminal fluid ACE (Fig 1A)
allowed us to suggest that different glycosylation of ACEs from different cells might occur in
the following glycosylation sites on ACE protein globule: Asn25 in the epitopes for mAbs BB9,
3A5 and i1A8, Asn289 in the epitopes for mAbs i2H5 and 6A12 on the N domain, Asn666 in
the epitopes for 1E10 and 4E3, and Asn685 in the epitope for 2H9 on the C domain.
As for the dramatic difference in binding of mAbs 1B8 and 3F10 to seminal fluid ACE and
lung ACE, it might be explained by the difference in glycosylation of Asn731, which is in the
center of the epitopes for these two mAbs on the C domain of ACE [30] or, alternatively, by the
presence of transmembrane anchor in some molecules of lung ACE, which influences the bind-
ing of these very mAbs to ACE [19, 30]. The presence of such molecules was demonstrated by
MALDI TOF analysis which revealed in lung ACE digested with trypsin a presence of not only
the C-terminal peptide 1190–1203 but also peptides 1204–1213 and even 1214–1227 (Table 1
and Fig 2). To estimate possible contamination of lung ACE with molecules carrying hydro-
phobic transmembrane anchor, we analyzed lung ACE preparation by phase separation in Tri-
ton X-114. About 90% of the enzyme was determined in water phase, while only 10% appeared
in organic phase. Therefore, the proportion of ACE molecules with transmembrane-anchor in
the pure lung ACE preparation is not high and we can conclude that the presence of anchor-
containing molecules in lung enzyme unlikely contributes to the observed difference in the
binding of mAbs to the C-region of ACE molecule.
In order to analyze the reasons for the differences in mAbs 1B8 and 3F10 binding with lung
and seminal fluid ACE further we compared conformational fingerprint of ACE from lung
homogenate with that from epididymis and prostate homogenates (Fig 1B and 1C), which
should have similar proportion of anchor-containing ACE molecules. This comparison clearly
demonstrates remarkable differences in conformation of ACE from lung and ACE from both
prostate and epididymis. Better binding of mAbs 1B8 and 3F10 to prostate and epididymal
ACE, compared to lung ACE, reproduces better binding of these mAbs to pure seminal fluid
ACE compared to pure lung ACE and most probably indicates different glycosylation (extent
or type) of Asn731 in ACE from the epithelial cells of prostate and epididymis than in lung
ACE from endothelial cells (Fig 1B and 1C).
The enhanced binding of these two mAbs, as well as mAb 1B3 (directed to the epitope on
the stalk region [43–44]), to epididymal and prostate ACE allows us to suggest that better
access of the stalk region to these mAbs may indicate on the better access of the stalk region in
ACE on the surface of epithelial cells of prostate and epididymis for ACE secretase as well and
may result in higher rate of shedding
Moreover, a comparison of the conformational fingerprints of epididymal and prostate
ACE with their seminal fluid ACE counterpart indicates that seminal fluid ACE could repre-
sent a mixture of ACE originated from epididymis and ACE originated from prostate. In sup-
port of this suggestion, we discovered by MALDI-TOF analysis of seminal fluid ACE digested
with trypsin (Table 1) a presence of two C-terminal peptides, a peptide with molecular mass
1533.8 (found among matching peptides for unspecific cleavage by FindPept tool) which corre-
sponds to the peptide 1190–1202 (calculated mass 1533.7) reported previously [45] and a pep-
tide with molecular mass 1689.8 which corresponds to the peptide 1190–1203 (calculated mass
Tissue Specificity of ACE
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Table 1. Observed [M+H]+ ions of unglycosylated peptides in the mass spectra of human ACE tryptic digests.
Lung ACE Seminal fluid ACE
Peptide Observed m/z Calculatedm/z Peptide Observed m/z Calculated m/z
53–71c 2191.1 2191.1 53–71c 2191.1 2191.1
54–71 2035.0 2035.0 54–71 2035.0 2035.0
97–107 1084.6 1084.6 97–107 1084.7 1084.6
127–132a 744.4 744.4 127–132a 744.4 744.4
133–151a 2135.1 2135.0 133–151a 2135.1 2135.0
152–187 4117.1 4117.0 152–187 4117.2 4117.0
152–187b 4133.0 4133.0 152–187b 4132.9 4133.0
188–199 1416.6 1416.6 188–199 1416.6 1416.6
200–230 3837.9 3837.9 200–230 3837.8 3837.9
231–236c 808.4 808.5 231–236c 808.5 808.5
241–245 678.4 678.4 241–245 678.4 678.4
296–326 3526.7 3526.7 296–326 3526.7 3526.7
296–326b 3542.7 3542.6 296–326b 3542.7 3542.6
327–340a 1767.8 1767.8 327–340a 1767.8 1767.8
327–341a,c 1895.9 1895.9 327–341a,c 1895.9 1895.9
342–346c 678.4 678.4 342–346c 678.4 678.4
351–373 2821.4 2821.3 351–373 2821.3 2821.3
351–373b 2837.4 2837.3 351–373b 2837.3 2837.3
374–380 799.5 799.5 374–380 799.5 799.5
381–407c 2852.5 2852.5 381–407c 2852.5 2852.5
382–407 2696.4 2696.4 382–407 2696.4 2696.4
408–413 686.4 686.4 408–413 686.5 686.4
433–446 1724.9 1724.9 433–446 1724.9 1724.9
447–453 808.4 808.4 447–453 808.4 808.4
459–467 1362.6 1362.6 459–467 1362.7 1362.6
468–479c 1362.7 1362.7 468–479c 1362.7 1362.7
470–479 1133.6 1133.6 470–479 1133.6 1133.6
490–500 1342.7 1342.7 490–500 1342.8 1342.7
490–517c 3429.5 3429.8
501–532c 3837.9 3837.8 501–532c 3837.8 3837.8
518–532a 1821.8 1821.8 518–532a 1821.8 1821.8
542–557c 1826.0 1826.0 542–557c 1826.0 1826.0
543–557 1697.9 1697.9 543–557 1697.9 1697.9
558–572 1598.9 1598.8 558–572 1598.9 1598.8
623–629 957.4 957.4 623–629 957.5 957.4
661–677c 1973.9 1974.0 661–677c 1973.8 1974.0
671–676 695.4 695.3 671–676 695.4 695.3
694–700c 887.5 887.5 694–700c 887.5 887.5
701–713 1475.8 1475.7 701–713 1475.8 1475.7
750–762c 1751.9 1751.9 750–762c 1751.9 1751.9
751–762 1623.8 1623.8 751–762 1623.8 1623.8
751–767c 2151.1 2151.0 751–767c 2151.1 2151.0
768–775 979.6 979.6 768–775 979.6 979.6
776–785 1176.7 1176.6 776–785 1176.7 1176.6
786–797 1352.6 1352.6 786–797 1352.6 1352.6
798–811 1697.9 1697.8 798–811 1697.9 1697.8
(Continued)
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1689.8). So, it is possible that the seminal fluid contains two somatic ACE forms—shorter form
of ACE (1202 residues) and common form (1203 residues), which can be produced differently
by epididymis and prostate or, alternatively, the shorter form could be the result of the second-
ary carboxypeptidase processing as suggested in [45].
Measurement of ACE activity in tissues homogenates prepared in equal conditions (tissue:
buffer = 1:9) revealed that prostate exhibited much lower content of ACE (44 mU/g), than epi-
didymis (720 mU/g), which ACE activity was comparable to that in lung—1063 mU/g with
ZPHL as a substrate. These values are in accordance with lower ACE protein content in pros-
tate than in epididymis reported earlier [11–12] and confirmed recently in the Human Protein
Atlas (www.proteinatlas.org), which demonstrates that epididymis exhibits at least 6-fold more
ACE expression than prostate. However, higher content of ACE in epididymis is likely com-
pensated by higher mass of prostate which leads to pretty equal content of ACE in both organs
[11] and perhaps explains why ACE in seminal fluid is considered to originate equally from
both organs [16]. This conclusion is supported by the comparison of conformational finger-
prints of prostate, epididymis and seminal fluid ACEs (Fig 1). It seems that the pattern of
mAbs binding to pure seminal fluid ACE represents a mixture of patterns of mAbs binding to
Table 1. (Continued)
Lung ACE Seminal fluid ACE
Peptide Observed m/z Calculatedm/z Peptide Observed m/z Calculated m/z
798–811b 1713.9 1713.8 798–811b 1713.8 1713.8
812–828 2117.2 2117.2 812–828 2117.2 2117.2
834–883 5562.0 5561.7 834–883 5561.3 5561.7
884–889 744.4 744.4 884–889 744.4 744.4
915–924 1133.6 1133.6 915–924 1133.6 1133.6
940–944c 678.4 678.4 940–944c 678.4 678.4
945–971a 3305.6 3305.6 945–971a 3305.5 3305.6
972–978 783.5 783.5 972–978 783.5 783.5
979–1001 2309.3 2309.2 979–1001 2309.2 2309.2
1002–1025 2693.3 2693.3 1002–1025 2693.3 2693.3
1031–1044 1754.9 1754.9 1031–1044 1755.0 1754.9
1045–1077c 4066.1 4066.1 1045–1077c 4066.0 4066.1
1047–1054 866.5 866.5 1047–1054 866.5 866.5
1055–1065 1524.7 1524.7 1055–1065 1524.7 1524.7
1068–1077 1129.6 1129.6 1068–1077 1129.6 1129.6
1078–1087 1035.5 1035.5 1078–1087 1035.5 1035.5
1088–1098 1315.7 1315.7 1088–1098 1315.7 1315.7
1099–1125 3089.5 3089.5 1099–1125 3089.4 3089.5
1181–1189 1056.5 1056.5 1181–1189 1056.5 1056.5
1190–1202 1533.7 1533.8
1190–1203 1689.8 1689.8 1190–1203 1689.8 1689.8
1204–1213 1014.5 1014.5
1214–1227 1532.8 1532.8
a Acrylamide adduct on cysteine.
b Oxidized methionine.
c Contains one or two missed cleavage(s) by trypsin.
Peptides that contain potential N-glycosylation sites are shown in bold.
doi:10.1371/journal.pone.0143455.t001
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prostate and epididymal ACE. Thus, epididymal ACE, but not prostate ACE, exhibited
enhanced binding of mAb 1E10 to the C domain of ACE, which is also characteristic for semi-
nal fluid ACE. As opposite, prostate ACE is characterized by lowered binding of mAbs BB9,
i1A8, and i2H5 to the N domain of ACE, which is characteristic for seminal fluid ACE as well
(Fig 1).
ACE in prostate homogenate, however, is also characterized by a very low binding of mAb
5F1, while the binding of this mAb to ACE in epididymal homogenate and to pure seminal
fluid ACE are rather high. The epitope for this mAb contains potential site of glycosylation,
Asn117 [29]. Moreover, another site of glycosylation, Asn480, is located close to the epitope for
mAb5F1 [29]. It was shown earlier [40] that, at least, in serum ACE Asn480 is glycosylated. So,
we could suggest that glycosylation of Asn117 and/or Asn480 is dramatically different in pros-
tate ACE in comparison to epididymal and lung ACEs (Fig 1B and 1C).
Fig 2. Amino acid sequences of the lung and seminal fluid ACEs. Peptides identified by MALDI TOF MS are shown in bold; potential sites of trypsin
cleavage are underlined; potential glycosylation sites are marked by green; zinc-recognizing motives are marked by red; putative glycopeptides are shaded.
doi:10.1371/journal.pone.0143455.g002
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As a whole, the results allow us to assume that seminal fluid ACE originates likely equally
from epididymis and prostate glandular epithelial cells.
Identification of N-linked glycosylation sites in lung and seminal fluid
ACEs
Somatic ACEs isolated from human lung and seminal fluid were digested with trypsin and the
resulting peptides were analyzed using MALDI TOF MS. After a primary search of matching
tryptic peptides with the MASCOT program, the protein sequence coverage was about 50% in
both cases. After finding additional matching peptides using the FindPept tool, the sequence
coverage became higher, 61% for the lung ACE and 59% for seminal fluid enzyme. Unglycosy-
lated peptides identified by the FindPept tool in the tryptic digest of the lung ACE are listed in
Table 1 and shown in Fig 2; four of these peptides contain potential glycosylation sites,
Asn131, 494, 666, and 1196. The same four peptides were found in the trypsin digest of seminal
fluid ACE (Table 1). It should be noted, however, that the intensity of the MS peak correspond-
ing to the peptide 661–677, containing Asn666 as a potential glycosylation site, was extremely
small, especially in the case of the lung ACE. It casts doubt on the classification of this peptide
to the unglycosylated ones.
Analysis of the mass spectra data with the GlycoMod tool allowed revealing several peaks
matching by mass potential glycopeptides in the lung ACE and seminal fluid ACE. After expert
revision, we limited the number of putative glycopeptides by several ones with the most favor-
able structures reported in UniCarbKB. The results are presented in Table 2. It is seen that in
some cases the interpretation could be rather equivocal, as the data could be attributed to dif-
ferent peptides within amino acid sequence of ACE. In a few cases, an observed peak could be
related to the glycopeptides with the same peptide structure but with different glycan moieties.
Nevertheless, we could state that asparagins 82, 117, 480, 648, 666, and 731 could be glyco-
sylated in human lung ACE. The glycosylated Asn82, 117, and 480 have been found previously
in human kidney ACE [26], while the glycosylated Asn480, 666, and 685 have been reported to
be present in human plasma ACE [40]. As the source of plasma ACE is mainly lung ACE [4–
5], we could assume that Asn685 in lung ACE may also be glycosylated. It is worth noting that
the peptide 661–677 containing Asn666 was also found among unglycosylated peptides in the
tryptic digest of the lung ACE (Table 1), although the intensity of the corresponding MS peak
was very small. Thus, we could not consider this definite N-glycosylation site Asn666 as fully
glycosylated, but rather as partially glycosylated. The peptides containing Asn82, 117, 480, 648,
and 731 were not found among unglycosylated peptides. So, these sites could be fully glycosy-
lated. There is still some uncertainty in referring the peptides with observedm/z 2468.1 to the
peptides containing Asn480 or Asn666, as well as peptide withm/z 5885.4 to the peptides con-
taining either Asn648 or Asn731. The putative N-glycosylation site Asn648 is not attributed to
any known epitope for mAbs to ACE, while the N-glycosylation site Asn731 is a part of the epi-
topes for mAbs 1B8 and 3F10 to the C domain of ACE (Fig 2). The remarkable difference in
the efficiency of these mAbs binding to the lung ACE and seminal ACE (Fig 1) convincingly
shows that the glycosylation of this definite Asn731 is different in the lung ACE and seminal
fluid ACE.
Similarly, asparagins in positions Asn117, 416, 648, 666, and 685 could be glycosylated in
human seminal fluid ACE. The peptide 661–677 containing Asn666 was also found among
unglycosylated peptides (Table 1), although the intensity of the corresponding MS peak was
very small (as in the case of the lung ACE), therefore, this site could be partially glycosylated.
Other Asn residues can be considered as fully glycosylated.
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Comparison of the data obtained for lung and seminal fluid ACEs shows that both enzymes
contain fully glycosylated Asn117, however, the structure of putative glycans is different, glycan
from seminal fluid ACE exhibiting more branches. Both ACEs could contain fully glycosylated
Asn648, the suggested glycans being similar in both cases. And, again, both ACEs could con-
tain partially glycosylated Asn666, but the structures of suggested glycans in these ACE forms
remarkably differ, glycans in seminal fluid ACE being more complicated. In addition, analysis
of the tryptic digest of lung ACE revealed also Asn82, 480, and 731 as occupied N-glycosylation
sites, while for seminal fluid ACE occupied N-linked glycosylation sites were found to be 416,
and 685. The difference in N-glycosylation of ACE from different sources can be the reason for
the remarkable difference in the efficacy of binding of some mAbs to these ACEs (Fig 1), i.e.
differences in local ACE conformation.
The N-glycosylation sites on the N and C domains of human ACE are shown in Fig 3. In
addition to the putative difference in ACE N-glycosylation revealed by the mass spectra analy-
sis, different N-glycosylation in ACE originated from lung endothelial cells and in ACE from
epithelial cells of prostate and epididymis can include Asn25, and 289 on the N domain, as
indicated by the mAbs binding.
Inhibition of seminal fluid and lung ACEs
We examined the effect of ACE inhibitors, enalaprilat (analogue of tripeptide) and teprotide
(nonapeptide), on enzymatic activity of pure lung and seminal fluid ACEs. Both ACEs were
equally inhibited by ACE inhibitors with IC50 about 6 nM for enalaprilat and 10 nM for tepro-
tide. We also tested the inhibitory effects of mAbs 3A5 and i2H5, anti-catalytic mAb to the N
domain [24, 27], and mAbs 1E10 and 4E3, anti-catalytic mAbs to the C-domain [30] on ACE
activity (Fig 4). Inhibitory effect of both mAbs to the N domain, 3A5 and i2H5, at tested con-
centrations was significant towards both ACEs only with a substrate ZPHL (Fig 4A and 4B).
Table 2. N-glycosylated peptides and glycan structures found by the GlycoMod tool in ACE from lung and seminal fluid using MS data.
Lung ACE
N-Glycosylation site Peptide Observed m/z Calculated m/z Putative glycan structures
Asn82 Ala72-Arg89 3853.9 3853.7 (HexNAc)2(NeuAc)1+(Man)3(GlcNAc)2
Asn117 Gln109-Arg120 3030.4 3030.3 (HexNAc)2(NeuAc)1+(Man)3(GlcNAc)2
Asn480 Asn480-Lys489 2468.0 (Hex)3+(Man)3(GlcNAc)2
and/or 2468.1
Asn666 Asn661-Lys670 2468.1 (HexNAc)2+(Man)3(GlcNAc)2
(Hex)5(HexNAc)4(NeuAc)1+(Man)3(GlcNAc)2 and/or
Asn648 Thr630-Lys655 5885.4 (Hex)4(HexNAc)4(Deoxyhexose)1(NeuAc)1+(Man)3(GlcNAc)2
and/or 5885.4
Asn731 Ile714-Arg749 5885.6 (Hex)4(HexNAc)2+(Man)3(GlcNAc)2 and/or
(Hex)3(HexNAc)2(Deoxyhexose)1+(Man)3(GlcNAc)2
Seminal fluid ACE
N-Glycosylation site Peptide Observed m/z Calculated m/z Putative glycan structures
Asn117 Gln109-Arg120 5469.1 5469.1 (Hex)5(HexNAc)5(Deoxyhexose)1(NeuAc)4+(Man)3(GlcNAc)2
Asn416 Val414-Lys427 3288.5 3288.5 (Hex)1(HexNAc)3+(Man)3(GlcNAc)2
Asn648 Thr630-Lys655 5885.2 5885.4 (Hex)5(HexNAc)4(NeuAc)1+(Man)3(GlcNAc)2 and/or
(Hex)4(HexNAc)4(Deoxyhexose)1(NeuAc)1+(Man)3(GlcNAc)2
Asn666 Asn661-Lys670 3245.4 3245.3 (Hex)3(HexNAc)2(NeuAc)1+(Man)3(GlcNAc)2 and/or
(Hex)2(HexNAc)2(Deoxyhexose)1(NeuAc)1+(Man)3(GlcNAc)2
Asn685 Lys677-Lys689 2765.3 2765.3 (Hex)2+(Man)3(GlcNAc)2
doi:10.1371/journal.pone.0143455.t002
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However, these mAbs can be considered as more effective towards seminal fluid ACE, as
reflected by a more prominent decrease in the sensitive parameter ZPHL/HHL ratio (Fig 4C),
this decrease indicating preferable inhibition of the N domain of ACE [22]. Inhibitory effect of
mAbs, anti-catalytic to the C domain, was epitope-, substrate-, and tissue-specific. Both mAbs,
1E10 and 4E3, more effectively inhibited ACEs with HHL as a substrate, mAb 4E3 causing
more noticeable effect than mAb 1E10 and more effectively inhibiting lung ACE activity (Fig
4A and 4B). However, an effect of these mAbs on ACE activity with ZPHL as a substrate was
rather paradoxical: the binding of anti-catalytic mAbs to the C domain of seminal fluid ACE,
but not to the lung ACE, caused reliable enhancement of ACE activity (Fig 4B). We can con-
sider this fact as an indication of the putative conformational changes in the N domain of
Fig 3. The structures of N and C domains of ACE with potential glycosylation sites and epitopes for mAbs.Human N domain structure was based on
PDB P2C6N and C domain structure—based on PDB 1O86. The epitopes were marked on the N and C domains according to [27–31, 41]. The positions of
the epitopes for some mAbs (12 out of 17) are shown by circles on both sides of domain globule. The potential sites of N-glycosylation, 9 on the N domain
and 6 on the C domain, are marked by green; Asn494 on the N domain is not seen while Asn1196 is not present in structure of the C domain. The
glycosylation sites which might be differently glycosylated in seminal fluid ACE and lung ACE are shown by arrows. Some amino acid residues are shown by
numbers according to [38] for orientation.
doi:10.1371/journal.pone.0143455.g003
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Fig 4. Effect of anti-catalytic mAbs on the activity of pure seminal fluid and lung ACEs. Pure seminal fluid and lung ACEs (5 mU/ml with ZPHL as a
substrate) were incubated with mAbs (10 ug/ml), which are anti-catalytic for the N-domain active center, i2H5 and 3A5 [27], and for the C domain active
center, 1E10 and 4E3 [30], of ACE. Residual ACE activity was determined with substrates HHL (A) and ZPHL (B) and is presented as the ratio of ACE
activity in the presence of mAbs to that without mAbs. Data are also presented as ZPHL/HHL ratio of ACE activity in the presence of mAbs to that without
mAbs (C). Results are the mean ± SD of 2–4 experiments, made in duplicates.
doi:10.1371/journal.pone.0143455.g004
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seminal fluid ACE, which are induced by the binding of mAbs to the adjacent C domain and
accompanied by the increase of ACE N domain activity.
Effect of potential ACE-binding partners on seminal and lung ACEs
How these remarkable differences in local conformation of seminal fluid and lung ACEs may
be converted into different regulation of the functions of these ACEs, including the regulation
of their shedding? We demonstrated recently that the rate of recombinant human ACE shed-
ding from the surface of CHO-ACE, HEK-ACE and endothelial cells in the presence of bovine
and human serum was dramatically diminished, up to 2-times. However, the extent of the
serum effect varied depending on the type of serum and cells (unpublished observation).
Recently, it was found that albumin may bind to ACE [46–47]. Bearing in mind that albu-
min concentration in the seminal fluid (1 mg/ml) is 50-fold less than in the blood [48] it was
very tempting to suggest that 50-fold increase in ACE concentration in seminal fluid is solely
explained by 50-fold decrease in albumin concentration. Therefore, we estimated the effect of
inactivated human plasma, inactivated seminal fluid, as well as pure human and bovine albu-
mins, on mAbs binding to pure lung and seminal fluid ACEs (Fig 5).
Effect of inactivated human plasma on mAbs binding to two types of ACE differed signifi-
cantly (Fig 5A), with seminal fluid ACE being more sensitive to the presence of plasma. Effect
of inactivated seminal fluid on mAbs binding to two types of ACE also showed more promi-
nent effect for seminal fluid ACE (Fig 5B), strengthening our suggestion that different confor-
mations of these ACEs can participate in different regulation of the functions of ACEs on
endothelial and epithelial cells. It is worth noting that only a small percentage of the overall
effect of plasma on mAbs binding to ACE could be attributed to albumin (Fig 5C), namely, a
decrease in binding of mAb i1A8, which is seen only for seminal fluid ACE. We also should
state that an effect of pure albumins is strongly species specific (Fig 5C and 5D). While the
effects of human and bovine albumins were rather equal on mAbs i1A8, 1E10, and 4E3 binding
to seminal fluid ACE, only bovine albumin caused the increase of mAbs i2H5, 1G12, and 6A12
(with overlapping epitopes) binding to this enzyme. Alternatively, only human albumin caused
the decrease of mAb 5F1 binding to lung ACE (without effect on the binding of other mAbs to
lung ACE), whereas bovine ACE caused multiple conformational changes in this ACE.
LMW component from blood also binds to ACE
We found that Low Molecular Weight (LMW) component from human plasma binds to
human ACE (unpublished observation). Therefore, we tested an effect of human plasma 3kDa
filtrate, containing LMW component (-s), on mAbs binding to both structurally different
ACEs and showed that this filtrate had a strong (and different) effect on both types of ACE
(Fig 6).
Comparison of the effect of 3 kDa human plasma filtrate (Fig 6B) with the effect of heat-
inactivated human plasma (Fig 6A) clearly demonstrates that LMW components of human
plasma exhibited more significant effect on mAbs binding to ACEs than proteins within this
plasma.
We identified recently a bilirubin as one of the components of 3 kDa plasma filtrate which
is able to bind to ACE in the region of the overlapping epitopes 1G12/6A12 (unpublished
observation). Therefore, we tested an effect of this novel ACE-binding partner, bilirubin, on
two different, tissue specific ACE types (alone or in combination with human albumin), seen
on Fig 6C and 6D. Again, the effect of bilirubin on ACE was strongly tissue specific: significant
effect of bilirubin on mAbs binding to the N domain of lung ACE, while less pronounced for
Tissue Specificity of ACE
PLOSONE | DOI:10.1371/journal.pone.0143455 November 23, 2015 15 / 21
seminal fluid ACE, and visible effect on the mAbs binding to the C domain of seminal fluid
ACE without any effect on the C domain of the lung ACE (Fig 6C).
The fact that human albumin practically abolished an effect of bilirubin on mAbs binding
to both ACEs (Fig 6D) shows that only unbound bilirubin (which represents only minor part
(about 10%) of total bilirubin content in the blood [49] can bind to ACE.
Thus, significant differences in local conformation of lung ACE (originated from endothe-
lial cells) and seminal fluid ACE (originated from epithelial cells of prostate and epididymis)
allow us to suggest that possible regulation of ACE shedding from epithelial cells of male repro-
ductive tract and from endothelial cells of capillaries (blood vessels) by the constituents of
blood and seminal fluid may be different due to different effect of possible regulators of ACE
shedding on the structurally different ACEs in these cells.
Fig 5. Effect of human plasma, seminal fluid and albumins onmAbs binding to ACEs. ACE activity immunoprecipitated by 17 mAbs to ACE (as in Fig 1)
was presented as a normalized value (“binding ratio”) to highlight differences in immunoprecipitation pattern (“conformational fingerprint”) after adding heat-
inactivated human citrated plasma, heat-inactivated seminal fluid, as well as human and bovine albumins to purified seminal fluid and lung ACEs with that
without additives.A-B. Effect of 20% of heat-inactivated human plasma (A) and heat-inactivated seminal fluid (B); C-D. Effect of human (C) and bovine (D)
albumins at concentrations of 8 mg/ml (similar to albumin concentration in 20% serum). Data are presented as in Fig 1.
doi:10.1371/journal.pone.0143455.g005
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In addition, membrane-bound glycoproteins (including ACE) may often be shed into blood
circulation as a by-product of the disease process. Recently an increase in blood ACE level was
demonstrated for patients with epithelial ovarian carcinoma [50]. Likely, such an increase may
be explained by an increase of local vascular permeability induced by the increased VEGF pro-
duction by tumor tissues.
Significant structural differences in ACE from endothelial cells (major source of blood
ACE) and ACE from epithelial cells, particularly prostate ACE (demonstrated in this study)
and, likely, ovary ACE, may be the base for the development of specific mAbs, which can be
used to identify the tissue- or-cell source of increased ACE in blood in different diseases. In
order to estimate the possibility of generating monoclonal antibodies which would discrimi-
nate between endothelial and epithelial ACEs we attempted immunization of mice with pure
Fig 6. Effect of different additives onmAbs binding to seminal fluid and lung ACEs. ACE activity immunoprecipitated by 17 mAbs to ACE (as in Fig 1)
was presented as a normalized value (“binding ratio”) to highlight differences in immunoprecipitation pattern (“conformational fingerprint”) after adding of
tested compounds to purified seminal fluid and lung ACEs with that without additives. (A) Effect of 20% of human heat-inactivated plasma. (B) Effect of 80%
3 kDa filtrate of human citrated plasma.C-D. Effect of bilirubin (150 ug/ml) in the absence (C) or presence (D) of human albumin at 8 mg/ml concentration
(which correspond to its concentration in 20% serum). Data are presented as in Fig 1.
doi:10.1371/journal.pone.0143455.g006
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somatic ACE from seminal fluid which is the mixture of prostate and epididymal ACEs [15–
16]. We used the hybridoma fusion technology to dissect the immune response based on pri-
mary screening of post-fusion populations. This would estimate the possibility of generation of
tissue ACE-specific antibodies and, eventually, establish antibody-producing hybridoma
clones. The results of primary screening of 670 post-fusion populations are shown in Fig 7. The
positive response was detected in 91 wells (Fig 7A). The 36% of positive populations reacted
rather equally with seminal fluid and lung ACEs (SF/Lung ratio equals to 0.5–1.5, i.e. no signif-
icant preference, Fig 7C). The 34% of positive populations demonstrated preference of different
degree towards seminal fluid ACE (Fig 7B), while 30% showed preference of different degree to
lung ACE (Fig 7D). Therefore, even at the level of polyclonal immune response against seminal
Fig 7. Primary immune response in mice to pure somatic ACE from seminal fluid. Culture fluids from 670 post-fusion cell populations grown in 96-well
plates (primary screening) were anylyzed for the presence of antibodies to seminal fluid ACE and lung ACE in parallel in plate precipitation assay (as in Fig
1). Presence of antibodies to seminal fluid and/or lung ACE was detected in 91 wells by precipitated ACE activity and the data are presented as the ratio of
ACE activity precipitation from seminal fluid ACE to that from lung ACE (SF/Lung ratio). Discrimination of these two ACEs by antibodies from these positive
wells was observed in a wide range (A). Besides expected antibodies, recognizing both ACEs (C) with SF/Lung ratio in the region from 0.5 to 1.5, we
identified significant proportions of antibodies which preferentially recognized seminal fluid ACE (B) with SF/Lung ratio more than 1.5, and antibodies which
preferentially recognized lung ACE (D) with SF/Lung ratio less than 0.5, correspondingly.
doi:10.1371/journal.pone.0143455.g007
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fluid ACE it was possible to detect spectrum of antibodies with different preferences to tissue
specific ACEs.
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